PI3King on MYCN to Improve Neuroblastoma Therapeutics

E-resources

PDF

Full text

Peer reviewed Open access

PI3King on MYCN to Improve Neuroblastoma Therapeutics

Hogarty, Michael D.; Maris, John M.

Cancer cell, 02/2012, Volume: 21, Issue: 2

Journal Article

MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN.

Keep searching

Author

Hogarty, Michael D. | Maris, John M.

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme